For Healthcare Professionals

A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis


About the study

This is a Phase 1b, 2-week study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of SB414 in subjects with mild to moderate AD.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


  1. Male or female, 18 years of age and older, and in good general health;
  2. EASI score >1 and ≤21, involving ≥5% body surface area (BSA).
  3. Two target lesions at least 5 cm2 with a TLSS ≥5. Target lesions can not be located on the groin, hands, elbows, feet, ankles, knees, face or scalp.
  4. Willing to not use any other products for AD during the study;
  5. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test (UPT) prior to randomization and must agree to use an effective method of birth control during the study and for 30 days after their final study visit.


  1. Concurrent or recent use of topical or systemic medications without a sufficient washout period;
  2. Immunocompromised subjects including those who are known HIV positive or receiving current immunosuppressive treatment,
  3. Female subjects who are pregnant, nursing mothers, or planning to become pregnant during the study;
  4. Active acute bacterial, fungal, or viral skin infection within 1 week before the baseline visit.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.
Phone iconCall 919-485-8080Email iconEmail Study Center

Study’s details


Atopic Dermatitis




Phase 1

Participants needed


Est. Completion Date

Nov 2018

Treatment type



Novan, Inc. identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.